News
-
-
-
PRESS RELEASE
Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
Research report on Pentixapharm Holding AG by NuWays AG highlights the potential breakthrough in diagnostic market with PentixaFor, a non-invasive PET scan for primary aldosteronism. Buy recommendation and target price of EUR 7.2 -
-
-
PRESS RELEASE
Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism
Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA -
-
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism
Pentixapharm Holding AG receives FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor for subtyping of Primary Aldosteronism, allowing more efficient regulatory review process -
